What can modern statistics offer imaging neuroscience?

Lange, Nicholas
October 2003
Statistical Methods in Medical Research;Oct2003, Vol. 12 Issue 5, p447
Academic Journal
journal article
This paper presents a mixed-effects model, region-of-interest analysis of a longitudinal functional magnetic resonance imaging (fMRI) study of drug effects on human memory function. A key region of interest is the human hippocampus, affected by brain disorders such as Alzheimer's disease and schizophrenia. A brief section on human hippocampal cell microscopy complements the discussion of the macroscopic fMRI study. Statistical issues confronted in these two applications are then placed in a broader context for further discussion of the future roles of biostatisticians and our methods in the fertile intersection of applied mathematical abstraction and imaging neuroscience. Neuroscientific and fMRI background is provided for readers new to either area.


Related Articles

  • Subcortical volume changes in dementia with Lewy bodies and Alzheimer's disease. A comparison with healthy aging. Watson, Rosie; Colloby, Sean J.; Blamire, Andrew M.; O’Brien, John T.; O'Brien, John T // International Psychogeriatrics;Apr2016, Vol. 28 Issue 4, p529 

    Background: Differentiating Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), two of the commonest forms of dementia in older age, remains a diagnostic challenge. To assist with better understanding of the differences between the conditions during life, we assessed limbic and...

  • The corpus callosum in first episode schizophrenia: a diffusion tensor imaging study. Price, G.; Bagary, M. S.; Cercignani, M.; Altmann, D. R.; Ron, M. A. // Journal of Neurology, Neurosurgery & Psychiatry;Apr2005, Vol. 76 Issue 4, p585 

    Background: Neuropathological and imaging studies suggest that corpus callosum abnormalities (CC) are present in schizophrenia, but it remains to be determined whether these abnormalities are present at illness onset. Diffusion tensor imaging (DTI), which is more sensitive than...

  • Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. Brück, A.; Kurki, T.; Kaasinen, V.; Vahlberg, T.; Rinne, J. O.; Brück, A // Journal of Neurology, Neurosurgery & Psychiatry;Oct2004, Vol. 75 Issue 10, p1467 

    Background: Early stage patients with Parkinson's disease (PD) show cognitive impairment in frontal lobe functions and memory tests. Hippocampal atrophy is seen in medicated patients with advanced PD.Objectives: To examine whether prefrontal or hippocampal atrophy are...

  • Clozapine treatment in patients with prior substance abuse. Kelly, Deanna L; Gale, Elizabeth A; Conley, Robert R // Canadian Journal of Psychiatry;Mar2003, Vol. 48 Issue 2, p111 

    Objective: This study examined outcomes following discharge on clozapine for treatment-resistant schizophrenia patients with and without diagnosed substance abuse histories.Methods: Those discharged on clozapine from a research unit between April 1991 and March 1996...

  • Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. McIntyre, Roger S.; Trakas, Kostas; Lin, Daryl; Balshaw, Robert; Hwang, Pieway; Robinson, Kimberly; Eggleston, Andrew // Canadian Journal of Psychiatry;Nov2003, Vol. 48 Issue 10, p689 

    Background: Antipsychotic-induced weight gain occurs in a substantial percentage of treated persons. There remains a paucity of naturalistic data that describe relative weight-gain liability with the available novel atypical antipsychotics (NAPs). This investigation describes...

  • Comparison of Hippocampal Volumes in Schizophrenia, Schizoaffective and Bipolar Disorder. Radonić, Elizabeta; Radoš, Marko; Kalember, Petra; Bajs-Janović, Maja; Folnegović-Šmalc, Vera; Henigsberg, Neven // Collegium Antropologicum;Mar2011 Supplement 1, Vol. 35, p249 

    The reduction of hippocampal volume was frequently reported in schizophrenia, but not in bipolar disorder. This volume reduction is associated with clinical features of schizophrenia, in particular with working and verbal memory impairments. Schizoaffective disorder, as a specific disorder...

  • Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Dursun, Serdar M; Gardner, David M; Bird, Diane C; Flinn, Janet; Dursun, S M; Gardner, D M; Bird, D C; Flinn, J // Canadian Journal of Psychiatry;Sep1999, Vol. 44 Issue 7, p701 

    Objective: This prospective, consecutive case-series outcome investigation evaluates the effectiveness of olanzapine in 16 patients with treatment-resistant schizophrenia. Method: Treatment resistance was defined as nonresponsiveness to at least 3 antipsychotic drugs...

  • Clinical aspects of substance abuse in persons with schizophrenia. Negrete, Juan C // Canadian Journal of Psychiatry;Feb2003, Vol. 48 Issue 1, p14 

    Objective: To review the current knowledge on the problem of psychoactive substance abuse by persons with schizophrenia, with particular attention to issues of direct relevance to clinical practice.Method: The author examined the literature from the last 2 decades and...

  • Weight gain and new onset diabetes associated with olanzapine and risperidone. Farwell, Wildon R.; Stump, Timothy E.; Wang, Jane; Tafesse, Eskinder; L'Italien, Gilbert; Tierney, William M. // JGIM: Journal of General Internal Medicine;Dec2004, Vol. 19 Issue 12, p1200 

    Objective: To assess whether newer antipsychotic medications are associated with weight gain and development of diabetes.Design: Retrospective cohort study.Setting: Data from a comprehensive electronic medical record serving an urban public hospital and a...

  • Long-term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia: further evidence. Kolivakis, Theodore T.; Beauclair, Linda; Margolese, Howard C.; Chouinard, Guy // Canadian Journal of Psychiatry;Apr2004, Vol. 49 Issue 4, p280 

    Presents a letter to the editor regarding the long-term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia further eveidence, published in the April 2004 issue of "The Canadian Journal of Psychiatry."


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics